Renalytix PLC - London-based diagnostics company, focused on prognosis services for patients with chronic kidney disease - Receives an unsolicited approach from a strategic acquiror which is evaluating a acquisition of the company's entire share capital. Renalytix describes the potential acquiror as a "large and well-capitalised publicly listed strategic diagnostics company". Renalytix has commenced a review of its options, including the sale of the company or its assets, and commenced a formal sale process. Renalytix says it may conclude that its interests are better served by other strategic options, including trading on AIM and Nasdaq as an independent entity, and therefore notes that there is no guarantee of the sale's completion.
Current stock price: 60.15 pence per share, up 50% in London on Monday afternoon.
12-month change: down 57%
By Hugh Cameron, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Renalytix Plc (RENX)